Nagilma (Metformin Hydrochloride, Linagliptin)

Metformin lowers blood glucose primarily by decreasing hepatic glucose production and increasing peripheral uptake of glucose. It activates AMP‑activated protein kinase (AMPK), which reduces gluconeogenesis and improves insulin sensitivity in muscle and adipose tissue.

The dose of Nagilma is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Only a qualified prescriber can determine the appropriate dosage regimen.

Safety of Nagilma in pregnancy and lactation has not been fully established. Metformin is sometimes used during pregnancy under specialist guidance, while linagliptin lacks sufficient data. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and benefits with their physician.

To order Nagilma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nagilma offers a fixed‑dose combination of metformin and linagliptin, providing both insulin‑sensitising and incretin‑based mechanisms in one tablet. Compared with metformin alone, it adds greater glucose‑lowering potency, and versus DPP‑4 inhibitor monotherapy, it includes the well‑established benefits of metformin, often reducing the need for multiple separate pills.

Nagilma should be stored at ambient temperature, below 25 °C, in its original blister pack or container. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

Nagilma is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypersensitivity reactions such as angio‑edema or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, or signs of an allergic reaction.

Nagilma is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), significant hepatic disease, known hypersensitivity to metformin or linagliptin, and in those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.